Durvalumab with chemotherapy as first line treatment in advanced pleural mesothelioma: A phase 3, randomised trial (DREAM3R).

被引：0
|
作者：
Forde, Patrick M.
Nowak, Anna K.
Hughes, Brett Gordon Maxwell
Kok, Peey Sei
Brown, Chris
Sun, Zhuoxin
Anagnostou, Valsamo
O'Byrne, Ken
Yip, Sonia
Cook, Alistair
Lesterhuis, Willem Joost
Pavlakis, Nick
Brahmer, Julie R.
Kindler, Hedy L.
Tsao, Anne S.
Zauderer, Marjorie Glass
Ramalingam, Suresh S.
Stockler, Martin R.
机构：
[1] Johns Hopkins Univ, Sidney Kimmel Comprehens Canc Ctr, Bloomberg Kimmel Inst Canc Immunotherapy, Baltimore, MD USA
[2] Univ Western Australia, Nedlands, WA, Australia
[3] Prince Charles Hosp, Brisbane, Qld, Australia
[4] Univ Sydney, NHMRC Clin Trials Ctr, Sydney, NSW, Australia
[5] Dana Farber Canc Inst, Boston, MA 02115 USA
[6] Johns Hopkins Kimmel Canc Ctr, Baltimore, MD USA
[7] Queensland Univ Technol, Princess Alexandra Hosp, Translat Res Inst, Brisbane, Qld, Australia
[8] Univ Sydney, NHMRC Clin Trials Ctr, Camperdown, NSW, Australia
[9] Univ Western Australia, Sch Med, Perth, WA, Australia
[10] Univ Western Australia, Natl Ctr Asbestos Related Dis, Perth, WA, Australia
[11] Univ Western Australia, Natl Ctr Asbestos Related Dis, Nedlands, WA, Australia
[12] North Shore Hlth Hub, Genesis Care, Sydney, NSW, Australia
[13] Johns Hopkins Kimmel Canc Ctr, Bloomberg Kimmel Inst Canc Immunotherapy, Baltimore, MD USA
[14] Univ Chicago, Chicago, IL 60637 USA
[15] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA
[16] Mem Sloan Kettering Canc Ctr, 1275 York Ave, New York, NY 10021 USA
[17] Emory Univ Hosp, Winship Canc Inst, 1364 Clifton Rd NE, Atlanta, GA 30322 USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2023年 / 41卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
TPS8599
引用
收藏
页数：1
相关论文
共 50 条
  • [41] EMPOWER-Lung 3: Phase 3 Study of Combinations of Cemiplimab and Chemotherapy in First-Line Treatment of Advanced NSCLC
    Gogishvili, M.
    Mobashery, N.
    Makharadze, T.
    Navarro, M.
    Snodgrass, P.
    Chen, H.
    Lowy, I.
    Rietschel, P.
    Lee, S.
    JOURNAL OF THORACIC ONCOLOGY, 2019, 14 (10) : S649 - S649
  • [42] POSEIDON: A Phase 3 Study of First-Line Durvalumab ± Tremelimumab plus Chemotherapy vs Chemotherapy Alone in Metastatic NSCLC
    Mok, T.
    Johnson, M.
    Garon, E.
    Peters, S.
    Soria, J.
    Wang, L.
    Jarkowski, A.
    Dennis, P.
    Zhou, C.
    JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (11) : S1974 - S1974
  • [43] POSEIDON: A phase 3 study of first-line Durvalumab ± Tremelimumab plus chemotherapy vs chemotherapy alone in metastatic NSCLC
    Thomas, M.
    Grohe, C.
    Eberhardt, W.
    Rawluk, J.
    Reck, M.
    Laack, E.
    Wesseler, C.
    Rittmeyer, A.
    Alt, J.
    Reinmuth, N.
    Griesinger, F.
    Kern, J.
    ONCOLOGY RESEARCH AND TREATMENT, 2018, 41 : 295 - 295
  • [44] Vorinostat in patients with advanced malignant pleural mesothelioma who have progressed on previous chemotherapy (VANTAGE-014): a phase 3, double-blind, randomised, placebo-controlled trial
    Krug, Lee M.
    Kindler, Hedy L.
    Calvert, Hilary
    Manegold, Christian
    Tsao, Anne S.
    Fennell, Dean
    Ohman, Ronny
    Plummer, Ruth
    Eberhardt, Wilfried E. E.
    Fukuoka, Kazuya
    Gaafar, Rabab M.
    Lafitte, Jean-Jacques
    Hillerdal, Gunnar
    Chu, Quincy
    Buikhuisen, Wieneke A.
    Lubiniecki, Gregory M.
    Sun, Xing
    Smith, Margaret
    Baas, Paul
    LANCET ONCOLOGY, 2015, 16 (04): : 447 - 456
  • [45] Tivantinib in combination with Carboplatin and Pemetrexed as first line treatment in patients with advanced non-squamous NSCLC or Malignant Pleural Mesothelioma: results of phase I trial
    Zucali, P. A.
    Simonelli, M.
    De Vincenzo, F.
    Fatuzzo, G.
    Bertossi, M.
    Perrino, M.
    Miggiano, C.
    Giordano, L.
    Bonifacio, C.
    Sposta, F. Mrakic
    Santoro, A.
    ANNALS OF ONCOLOGY, 2015, 26 : 78 - 78
  • [46] Phase 3, randomised, open-label study of durvalumab (MEDI4736) in combination with tremelimumab versus platinum-based chemotherapy in first-line treatment of patients with advanced or metastatic NSCLC: NEPTUNE
    Mok, T.
    Schmid, P.
    Aren, O.
    Arrieta, O.
    Gottfried, M.
    Jazieh, A. R.
    Ramlau, R.
    Timcheva, C.
    Martin, C.
    Zhao, L.
    McIntosh, S.
    ANNALS OF ONCOLOGY, 2015, 26 : 147 - 147
  • [47] FURVENT, Phase 3 Trial Testing Furmonertinib vs Chemotherapy as First-Line Treatment for Advanced NSCLC with EGFR exon 20 Insertions
    Spira, A. I.
    Cho, B. C.
    Felip, E.
    Garon, E. B.
    Goto, K.
    Johnson, M. L.
    Leighl, N. B.
    Passaro, A.
    Planchard, D.
    Popat, S.
    Yang, J.
    Lu, X.
    Jiang, Y.
    Huang, J.
    Lam, M.
    Kowanetz, M.
    Wang, S.
    Le, J.
    Hsu, J. Y.
    Zhou, C.
    JOURNAL OF THORACIC ONCOLOGY, 2023, 18 (11) : S339 - S339
  • [48] Publisher Correction: Toripalimab or placebo plus chemotherapy as first-line treatment in advanced nasopharyngeal carcinoma: a multicenter randomized phase 3 trial
    Hai-Qiang Mai
    Qiu-Yan Chen
    Dongping Chen
    Chaosu Hu
    Kunyu Yang
    Jiyu Wen
    Jingao Li
    Ying-Rui Shi
    Feng Jin
    Ruilian Xu
    Jianji Pan
    Shenhong Qu
    Ping Li
    Chunhong Hu
    Yi-Chun Liu
    Yi Jiang
    Xia He
    Hung-Ming Wang
    Wan-Teck Lim
    Wangjun Liao
    Xiaohui He
    Xiaozhong Chen
    Zhigang Liu
    Xianglin Yuan
    Qi Li
    Xiaoyan Lin
    Shanghua Jing
    Yanju Chen
    Yin Lu
    Ching-Yun Hsieh
    Muh-Hwa Yang
    Chia-Jui Yen
    Jens Samol
    Hui Feng
    Sheng Yao
    Patricia Keegan
    Rui-Hua Xu
    Nature Medicine, 2022, 28 : 214 - 214
  • [49] Tislelizumab Plus Chemotherapy as First-Line Treatment for Locally Advanced or Metastatic Nonsquamous NSCLC (RATIONALE 304): A Randomized Phase 3 Trial
    Lu, Shun
    Wang, Jie
    Yu, Yan
    Yu, Xinmin
    Hu, Yanping
    Ai, Xinghao
    Ma, Zhiyong
    Li, Xingya
    Zhuang, Wu
    Liu, Yunpeng
    Li, Weidong
    Cui, Jiuwei
    Wang, Dong
    Liao, Wangjun
    Zhou, Jianying
    Wang, Zhehai
    Sun, Yuping
    Qiu, Xiusong
    Gao, Jie
    Bao, Yuanyuan
    Liang, Liang
    Wang, Mengzhao
    JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (09) : 1512 - 1522
  • [50] Tislelizumab plus chemotherapy versus placebo plus chemotherapy as first line treatment for advanced gastric or gastro-oesophageal junction adenocarcinoma: RATIONALE-305 randomised, double blind, phase 3 trial
    Qiu, Miao-Zhen
    Oh, Do-Youn
    Kato, Ken
    Arkenau, Tobias
    Tabernero, Josep
    Correa, Marcia Cruz
    Zimina, Anastasia, V
    Bai, Yuxian
    Shi, Jianhua
    Lee, Keun-Wook
    Wang, Jufeng
    Poddubskaya, Elena
    Pan, Hongming
    Rha, Sun Young
    Zhang, Ruixing
    Hirano, Hidekazu
    Spigel, David
    Yamaguchi, Kensei
    Chao, Yee
    Wyrwicz, Lucjan
    Disel, Umut
    Cid, Roberto Pazo
    Fornaro, Lorenzo
    Evesque, Ludovic
    Wang, Hongwei
    Xu, Yaling
    Li, Jiang
    Sheng, Tao
    Yang, Silu
    Li, Liyun
    Moehler, Markus
    Xu, Rui-Hua
    BMJ-BRITISH MEDICAL JOURNAL, 2024, 385
12345